Coya Therapeutics' Investigational New Drug To Treat Frontotemporal Dementia Receives FDA's Acceptance

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that the U.S. Food and Drug Administration (FDA) has accepted the Company's IND for COYA 302 for the treatment of frontotemporal dementia (FTD).

FTD is the most common form of dementia in people under the age of 65, affecting about 60,000 Americans. The average age of onset is 58, with an average survival time of 7.5 years. FTD is characterized by loss of intellectual functions, such as memory problems, impaired abstract thinking, reasoning, and executive function, that are severe enough to hamper activities of daily living. The clinical manifestations include behavior changes, dietary changes, loss of empathy, apathy, and executive function. FTD constitutes a high unmet medical need, as there is no treatment to stop or ameliorate the progression of the disease.